S&P 500   3,962.43 (+0.72%)
DOW   33,823.81 (+0.67%)
QQQ   283.65 (+1.11%)
AAPL   142.82 (+1.33%)
MSFT   247.36 (+1.22%)
META   115.97 (+1.79%)
GOOGL   94.14 (-0.84%)
AMZN   89.96 (+1.70%)
TSLA   170.57 (-1.99%)
NVDA   167.90 (+4.16%)
NIO   13.22 (+5.09%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.17 (-0.67%)
MU   55.44 (+3.01%)
CGC   3.17 (-2.16%)
F   13.13 (+0.23%)
GE   83.57 (-1.68%)
DIS   92.69 (+0.59%)
AMC   6.25 (+3.31%)
PYPL   75.30 (+1.18%)
PFE   51.08 (+1.67%)
NFLX   307.53 (-0.29%)
S&P 500   3,962.43 (+0.72%)
DOW   33,823.81 (+0.67%)
QQQ   283.65 (+1.11%)
AAPL   142.82 (+1.33%)
MSFT   247.36 (+1.22%)
META   115.97 (+1.79%)
GOOGL   94.14 (-0.84%)
AMZN   89.96 (+1.70%)
TSLA   170.57 (-1.99%)
NVDA   167.90 (+4.16%)
NIO   13.22 (+5.09%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.17 (-0.67%)
MU   55.44 (+3.01%)
CGC   3.17 (-2.16%)
F   13.13 (+0.23%)
GE   83.57 (-1.68%)
DIS   92.69 (+0.59%)
AMC   6.25 (+3.31%)
PYPL   75.30 (+1.18%)
PFE   51.08 (+1.67%)
NFLX   307.53 (-0.29%)
S&P 500   3,962.43 (+0.72%)
DOW   33,823.81 (+0.67%)
QQQ   283.65 (+1.11%)
AAPL   142.82 (+1.33%)
MSFT   247.36 (+1.22%)
META   115.97 (+1.79%)
GOOGL   94.14 (-0.84%)
AMZN   89.96 (+1.70%)
TSLA   170.57 (-1.99%)
NVDA   167.90 (+4.16%)
NIO   13.22 (+5.09%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.17 (-0.67%)
MU   55.44 (+3.01%)
CGC   3.17 (-2.16%)
F   13.13 (+0.23%)
GE   83.57 (-1.68%)
DIS   92.69 (+0.59%)
AMC   6.25 (+3.31%)
PYPL   75.30 (+1.18%)
PFE   51.08 (+1.67%)
NFLX   307.53 (-0.29%)
S&P 500   3,962.43 (+0.72%)
DOW   33,823.81 (+0.67%)
QQQ   283.65 (+1.11%)
AAPL   142.82 (+1.33%)
MSFT   247.36 (+1.22%)
META   115.97 (+1.79%)
GOOGL   94.14 (-0.84%)
AMZN   89.96 (+1.70%)
TSLA   170.57 (-1.99%)
NVDA   167.90 (+4.16%)
NIO   13.22 (+5.09%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.17 (-0.67%)
MU   55.44 (+3.01%)
CGC   3.17 (-2.16%)
F   13.13 (+0.23%)
GE   83.57 (-1.68%)
DIS   92.69 (+0.59%)
AMC   6.25 (+3.31%)
PYPL   75.30 (+1.18%)
PFE   51.08 (+1.67%)
NFLX   307.53 (-0.29%)
NASDAQ:MTEM

Molecular Templates - MTEM Stock Forecast, Price & News

$0.47
+0.01 (+2.28%)
(As of 12/8/2022 11:34 AM ET)
Add
Compare
Today's Range
$0.47
$0.50
50-Day Range
$0.46
$0.80
52-Week Range
$0.44
$4.45
Volume
1,092 shs
Average Volume
209,733 shs
Market Capitalization
$26.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.83

Molecular Templates MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
726.1% Upside
$3.83 Price Target
Short Interest
Healthy
0.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
-0.05mentions of Molecular Templates in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.52) to ($1.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

241st out of 1,027 stocks

Pharmaceutical Preparations Industry

103rd out of 503 stocks

MTEM stock logo

About Molecular Templates (NASDAQ:MTEM) Stock

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Stock News Headlines

See More Headlines
Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Company Calendar

Last Earnings
11/10/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MTEM
CUSIP
88580720
Employees
261
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$3.83
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+707.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-83,010,000.00
Net Margins
-231.40%
Pretax Margin
-230.40%

Debt

Sales & Book Value

Annual Sales
$38.70 million
Book Value
$1.17 per share

Miscellaneous

Free Float
40,348,000
Market Cap
$26.74 million
Optionable
Not Optionable
Beta
1.14

Social Links


Key Executives

  • Dr. Eric E. Poma Ph.D. (Age 50)
    CEO, Chief Scientific Officer & Director
    Comp: $839.67k
  • Ms. Jason S KimMs. Jason S Kim (Age 47)
    Pres & COO
    Comp: $600.41k
  • Dr. Roger J. Waltzman M.B.A. (Age 54)
    M.D., Chief Medical Officer
    Comp: $594.17k
  • Mr. Sean McLennan (Age 51)
    Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer
  • Ms. Megan C. Filoon
    Gen. Counsel & Sec.
  • Mr. Kurt Elster (Age 55)
    Exec. VP of Corp. Devel.
  • Dr. Jack Higgins Ph.D. (Age 42)
    Exec. VP of Operations & Head of Manufacturing
  • Dr. Erin Willert Ph.D. (Age 40)
    Exec. VP of R&D
  • Dr. Jen-Sing Liu Ph.D. (Age 59)
    Exec. VP of Manufacturing
  • Mr. Michael Dowd
    Sr. VP of Project & Alliance Management













MTEM Stock - Frequently Asked Questions

Should I buy or sell Molecular Templates stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MTEM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MTEM, but not buy additional shares or sell existing shares.
View MTEM analyst ratings
or view top-rated stocks.

What is Molecular Templates' stock price forecast for 2023?

2 Wall Street analysts have issued 12-month price objectives for Molecular Templates' stock. Their MTEM share price forecasts range from $1.00 to $9.00. On average, they predict the company's share price to reach $3.83 in the next year. This suggests a possible upside of 707.7% from the stock's current price.
View analysts price targets for MTEM
or view top-rated stocks among Wall Street analysts.

How have MTEM shares performed in 2022?

Molecular Templates' stock was trading at $3.92 at the start of the year. Since then, MTEM shares have decreased by 87.9% and is now trading at $0.4746.
View the best growth stocks for 2022 here
.

Are investors shorting Molecular Templates?

Molecular Templates saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 429,100 shares, a drop of 19.6% from the October 31st total of 533,500 shares. Based on an average daily volume of 105,500 shares, the days-to-cover ratio is currently 4.1 days. Currently, 1.0% of the shares of the company are sold short.
View Molecular Templates' Short Interest
.

When is Molecular Templates' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our MTEM earnings forecast
.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) released its quarterly earnings data on Thursday, November, 10th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.04. The biotechnology company earned $4.24 million during the quarter, compared to the consensus estimate of $4 million. Molecular Templates had a negative trailing twelve-month return on equity of 226.71% and a negative net margin of 231.40%.

When did Molecular Templates' stock split?

Shares of Molecular Templates reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.11%), Renaissance Technologies LLC (1.03%), Kingsbury Capital Investment Advisors LLC (0.53%), Two Sigma Advisers LP (0.45%) and Two Sigma Investments LP (0.39%). Insiders that own company stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii, Sean Mclennan, Shv Management Services, Llc and Target N V Biotech.
View institutional ownership trends
.

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $0.47.

How much money does Molecular Templates make?

Molecular Templates (NASDAQ:MTEM) has a market capitalization of $26.74 million and generates $38.70 million in revenue each year. The biotechnology company earns $-83,010,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does Molecular Templates have?

The company employs 261 workers across the globe.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529.

This page (NASDAQ:MTEM) was last updated on 12/8/2022 by MarketBeat.com Staff